We found that the PD-L1- DCs located closer to the PD-L1- tumor cells compared with PD-L1+ DCs both at baseline and during the combination treatment (baseline, p = 0.008; on-treatment, p = 0.016, Figure 4E and Table 2). Here, CD274 is linked to neoplasm.